

Serial No.: 07/715,397

On page 66, line 28, kindly insert -- SEQ ID NO 1 -- after "...LLK".

On page 67, line 24, kindly insert -- SEQ ID NO 1 -- after "...LLK".

On page 67, line 27, kindly insert -- SEQ ID NO 1 -- after "...LLK".

IN THE CLAIMS:

1. (Amended) A synthetic pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with a linear polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula $(Z_a U_b)_c Z_d$, wherein:

Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;

U is a hydrophobic amino acid residue independently selected from the group consisting of V, I, L, C, Y and F;

a has an average value of about 1 to about 5;

b has an average value of about 3 to about 20;

c is 1 to 10; and

d is 1 to 3;

said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

Kindly add new claims 6, 7, and 8, as follows:

6. A synthetic pulmonary surfactant comprising two pharmaceutically acceptable phospholipids admixed with a fatty acid and a polypeptide having an amino acid residue sequence represented by the formula:

KLLLLKLLLLKLLLLKLLLLK.

Serial No.: 07/715,397

7. A synthetic pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with a linear polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula $(Z_a U_b)_c Z_d$, wherein:

Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;

U is a hydrophobic amino acid residue independently selected from the group consisting of L and C;

a is 1 or 2;

b has an average value of about 3 to about 8;

c is 1 to 10; and

d is 0 to 2;

said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone.

8. The synthetic pulmonary surfactant of claim 7, said polypeptide having an amino acid residue sequence selected from the group consisting of:

RLLLLRLLLLRLLLLRLLLLR,
 RLLLLLLLLRLLLLLLLLRLL,
 RLLLLLLLLRLLLLLLLLRRL,
 RLLLCLLRLLLCLLR,
 RLLLCLLRLLLCLLRLL,
 RLLLCLLRLLLCLLRLLLCLLR,
 KLLLLKLLLLKLLLLKLLLLK,
 KLLLLLLLLKLLLLLLLLKLL, and
 KLLLLLLLLKKLLLLLLLLKKL.